share_log

港股异动 | 联邦制药(03933)涨超3% 胰岛素集采全线A组中标 机构看好其加速放量

Changes in Hong Kong stocks | Federal Pharmaceuticals (03933) rose more than 3%, and the winning bidder in Group A across the insulin collection line is optimistic about its accelerated release

Zhitong Finance ·  Apr 25 15:11

Federal Pharmaceuticals (03933) rose more than 3%. As of press release, it rose 3.41% to HK$9.71, with a turnover of HK$22.403,900.

The Zhitong Finance App learned that Federal Pharmaceuticals (03933) rose more than 3%. As of press release, it had risen 3.41% to HK$9.71, with a turnover of HK$22.403,900.

According to the news, on April 23, the six insulin products declared by Federal Pharmaceuticals were selected as Class A during the continuation of the special national procurement process for insulin. According to the company, the prices of the products to be selected by the company have been lowered moderately compared to the sixth batch of centralized procurement of national drugs (insulin special), but the procurement base volume has increased significantly by 52.5%. At the same time, all of the company's Class A selected products will also receive the remaining distribution amount.

In 2023, the total sales of the products to be selected by the company were RMB 1,117.6 billion, accounting for 22.2% of the company's pharmaceutical product revenue. According to Guojin Securities, the six federal pharmaceuticals' product line has been selected as Class A, and it is expected that this collection will be used to accelerate the volume of sales.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment